Skip to content

Study · Measured the body's own peptide · 1995

2 results

Expression of mRNA for vasoactive intestinal peptide in normal human colon and during inflammation.

Schulte-Bockholt A, Fink JG, Meier DA, Otterson MF, Telford GL, Hopp K, Koch TR

Molecular and cellular biochemistry1 Jan 1995Cited by 11 (Europe PMC)

PMID7753037 (opens in a new tab)DOI10.1007/bf00928907 (opens in a new tab)PepBankPUB-07753037
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with ulcerative colitis, tissue levels of the body's own VIP were lower in the mucosal-submucosal layer of the colon than in controls.

    In plain wordsIn people with ulcerative colitis, natural VIP levels in the inner colon wall were lower than in people without it.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseTissue VIP in mucosal-submucosal layer of colon
    Study

    n = 12

    Comparator
    Controls
    Outcome group
    Inflammation markers · Gastrointestinal

    Source sentences

    Summary
    Tissue vasoactive intestinal peptide was decreased only in the mucosal-submucosal layer of ulcerative colitis (p = .02).
    1 context sentence
    Summary · context
    Sigmoid colon was obtained at surgery from controls (n = 6) and patients with ulcerative colitis (n = 6). Vasoactive intestinal peptide mRNA was quantified by Northern blot hybridization and tissue levels of vasoactive intestinal peptide were determined by radioimmunoassay.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with ulcerative colitis, normalised VIP mRNA in the colon was 260% higher than in controls.

    In plain wordsIn people with ulcerative colitis, the gene signal for the body's own VIP in the colon was higher than in people without it.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVIP mRNA in colon
    Study

    n = 12

    Comparator
    Controls
    Outcome group
    Inflammation markers · Gastrointestinal

    Measurements

    VIP mRNA increase
    260%
    ulcerative colitis versus controls

    Source sentences

    Summary
    Normalized vasoactive intestinal peptide mRNA levels were increased by 260% in ulcerative colitis compared to controls (p < .01).
    1 context sentence
    Summary · context
    Sigmoid colon was obtained at surgery from controls (n = 6) and patients with ulcerative colitis (n = 6). Vasoactive intestinal peptide mRNA was quantified by Northern blot hybridization and tissue levels of vasoactive intestinal peptide were determined by radioimmunoassay.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.